A Phase 3 interventional study of Ibuprofen/famotidine and Ibuprofen in Ulcer, sponsored by Amgen. Completed. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Amgen · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. The study is designed to determine whether the combination product reduces the rate of ulcer development in subjects who require long-term daily use of ibuprofen.
Subjects will be assigned randomly, in approximately a 2:1 ratio, to treatment with either HZT-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen (800 mg) three times daily for a 24 week treatment period or until they develop either an endoscopically-diagnosed upper gastrointestinal ulcer and/or prohibitive toxicity. Subjects will visit the study center for Screening and at Weeks 4, 8, 16, and 24. Physical exams will be performed, and clinical laboratory measurements made, at selected times during the study. Endoscopic exams will be performed during Screening and at Weeks 8, 16, and 24. Subjects will be contacted four weeks following study completion.
Study with completed results acquired from Horizon in 2024.
359 studies on the registry are indexed under Ulcer; 60 are open to participants now.
This study's enrollment of 906 is above the median of 65 across 291 interventional studies indexed under Ulcer.
Browse Ulcer studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of any of the following serious gastrointestinal complications:
Please note that there are other additional criteria. The study center will determine if patients meet all of the criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HZT-501: Ibuprofen 800mg/famotidine 26.6mg
Drug: Ibuprofen/famotidine
Ibuprofen 800mg
Drug: Ibuprofen
Drug pages: Ibuprofen · Famotidine
HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
Ibuprofen 800mg administered orally 3 times daily for 24 weeks
Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
Time frame: 24 weeks
Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
Time frame: 24 weeks
Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
Time frame: 24 weeks
The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.
Time frame: 24 weeks
| Milestone | HZT-501 | Ibuprofen |
|---|---|---|
| Started | 607 | 299 |
| Completed | 433 | 170 |
| Not completed | 174 | 129 |
| Withdrew: Adverse event | 38 | 23 |
| Withdrew: Withdrawal by subject | 48 | 26 |
| Withdrew: Lost to follow-up | 16 | 9 |
| Withdrew: Upper gastrointestinal (ugi) ulcer | 51 | 51 |
| Withdrew: Misc | 21 | 20 |
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
| participants | HZT-501 | Ibuprofen |
|---|---|---|
| Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers | 55 (4.4 to 15.3) | 52 (4.4 to 15.3) |
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
| participants | HZT-501 | Ibuprofen |
|---|---|---|
| Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period. | 63 (6.1 to 17.6) | 61 (6.1 to 17.6) |
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.
| participants | HZT-501 | Ibuprofen |
|---|---|---|
| Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period. | 8 (1.0 to 6.8) | 14 (1.0 to 6.8) |
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.
| particpants | HZT-501 | Ibuprofen |
|---|---|---|
| The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding) | 3 | 0 |
Collected over Randomization to 28 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HZT-501 | — | 22/607 (3.6%) | 342/607 (56.3%) |
| Ibuprofen | — | 13/299 (4.3%) | 184/299 (61.5%) |
| Event | HZT-501 | Ibuprofen |
|---|---|---|
| cardio-respiratory arrestCardiac disorders | 0/607 | 2/299 |
| pneumoniaInfections and infestations | 1/607 | 2/299 |
| renal failure acuteRenal and urinary disorders | 3/607 | 0/299 |
| benign neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/607 | 1/299 |
| bipolar disorderPsychiatric disorders | 0/607 | 1/299 |
| bronchitsInfections and infestations | 0/607 | 1/299 |
| chest painGeneral disorders | 2/607 | 1/299 |
| coronary artery diseaseCardiac disorders | 0/607 | 1/299 |
| depressionPsychiatric disorders | 1/607 | 1/299 |
| drug toxicityInjury, poisoning and procedural complications | 0/607 | 1/299 |
| Event | HZT-501 | Ibuprofen |
|---|---|---|
| dyspepsiaGastrointestinal disorders | 31/607 | 23/299 |
| nauseaGastrointestinal disorders | 40/607 | 13/299 |
| diarrheaGastrointestinal disorders | 30/607 | 13/299 |
| constipationGastrointestinal disorders | 27/607 | 13/299 |
| headacheNervous system disorders | 23/607 | 9/299 |
| upper respiratory tract infectionInfections and infestations | 23/607 | 10/299 |
| sinusitisInfections and infestations | 12/607 | 11/299 |
| hypertensionVascular disorders | 21/607 | 7/299 |
| abdominal pain upperGastrointestinal disorders | 20/607 | 7/299 |
| coughRespiratory, thoracic and mediastinal disorders | 12/607 | 9/299 |
| Age, Categorical(Participants) | HZT-501 | Ibuprofen | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 500 | 240 | 740 |
| >=65 years | 107 | 59 | 166 |
| Age, Continuous(years) | HZT-501 | Ibuprofen | Total |
|---|---|---|---|
| Mean | 55.5 ± 9.2 | 55.9 ± 9.3 | 55.6 ± 9.2 |
| Sex: Female, Male(Participants) | HZT-501 | Ibuprofen | Total |
|---|---|---|---|
| Female | 416 | 208 | 624 |
| Male | 191 | 91 | 282 |
| Region of Enrollment(participants) | HZT-501 | Ibuprofen | Total |
|---|---|---|---|
| United States | 607 | 299 | 906 |
No study locations are listed for this record.
The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuprofen · Famotidine